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On the verge of this year’s German So-
ciety of Rheumatology congress in Bo-
chum, the new German guidelines for the 
medical treatment of rheumatoid arthritis 
have been published [1]. Based on the 2010 
EULAR recommendations (EUropean 
League Against Rheumatism) [2] and sub-
sequent evidence from an additional sys-
tematic literature research [3] and expert 
consensus, they provide not only infor-
mation concerning state-of-the-art treat-
ment of rheumatoid arthritis (RA) but al-
so a modification of the hitherto common 
treatment algorithm in Germany [4].
Although the predominant part of the 
single EULAR recommendations remains 
unchanged, recent data from the current 
systematic literature research resulted in 
distinct rephrasing of the original EU-
LAR recommendations (. Tab. 1, 2). In 
addition, differences in the German stat-
uary order and a somewhat different sta-
tus of approval have been followed. These 
new guidelines have been approved by a 
Hot Topics
Tab. 1 German 2012 recommendations for the medical treatment of rheumatoid arthritis
Overarching principles
A Rheumatologists are the specialists who should primarily care for patients with RA
B Treatment of patients with RA should aim at the best care and is based on a shared decision between the patient and the rheumatologist
C RA is expensive in regards to direct and indirect costs both of which should be considered by the treating rheumatologist
12 recommendations for the medical treatment of RA
1 Treatment with conventional DMARDs should be started as soon as the diagnosis of RA is made
2 The target of remission or low disease activity should be reached as soon as possible. As long as the target has not been reached, adjustment of 
treatment and frequent monitoring is necessary
3 MTX should be the first DMARD in patients with active RA
4 When MTX cannot be used as first treatment, another conventional DMARD, e.g., leflunomide or sulfasalazine, should be considered
5 Initial combination therapy with conventional DMARDs has not demonstrated advantages to monotherapy in patients with active RA
6 Glucocorticoids should be added to the initial treatment with conventional DMARDs at low to moderately high doses
7 If the treatment target is not achieved despite optimized DMARD monotherapy, a combination therapy with conventional DMARDs should be 
considered. In case of high disease activity, especially in combination with poor prognostic factors, combination with a biological DMARD should be 
considered
8 After failure of two conventional DMARDs (in monotherapy or in combination), a biologic therapy is recommended
9 Patients with active RA, for whom a TNF inhibitor has failed as the first biologic DMARD, can switch to another TNF inhibitor, abatacept, rituximab, or 
tocilizumab
10 In case of refractory RA or contraindications to the previously mentioned conventional or biologic DMARDs, other DMARDs and immunmodulated 
therapies can be considered
11 In case of sustained remission, a stepwise tapering of the DMARD therapy should be considered as a shared decision between patient and doctor
12 Apart from disease activity, factors such as structural progression, comorbidities, safety concerns, and social aspects should be taken into account
RA rheumatoid arthritis, DMARDs disease-modifying antirheumatic drugs, MTX methotrexate, TNF tumor necrosis factor.
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committee of national experts and the ex-
ecutive committee of the German Soci-
ety of Rheumatology, who have discussed 
and voted upon the final set of the recom-
mendations.
The national experts agreed to leave 
the overarching principles and the first 
two EULAR recommendations without 
modification. They refer to the quickest-
possible diagnosis and treatment of rheu-
matoid arthritis at its best in accordance 
with the patient and the rheumatologist, 
targeting early remission and with respect 
to direct and indirect costs. Furthermore, 
it was beyond any doubt that according to 
recommendation 3, methotrexate should 
be part of the first treatment strategy.
In case of methotrexate contraindica-
tion or intolerance, leflunomide and sul-
fasalazine are considered part of the first 
treatment strategy in both recommenda-
tions. However, injectable gold is not rec-
ommended in the current German guide-
lines. The main reason for not following 
the EULAR recommendation in this as-
pect and despite the available high-level 
evidence for the efficacy of injectable gold 
was the decreasing experience of the rheu-
matologists and the considerable side ef-
fects in long-term use.
In contrast to previous decisions, EU-
LAR recommendation 5 took for the first 
time a firm stand towards a DMARD 
monotherapy (disease-modifying anti-
rheumatic drug) rather than a combina-
tion therapy of synthetic DMARDs. In 
fact, no clinical study has demonstrat-
ed a significant advantage of combina-
tion therapy over monotherapy in the ab-
sence of glucocorticoids. Nevertheless, the 
EULAR recommendation also states that 
while in DMARD naïve patients the bal-
ance of efficacy and toxicity favors mono-
therapy, the respective evidence is incon-
clusive in DMARD inadequate respond-
ers. Here, the German guidelines on-
ly state the lacking evidence for the ad-
vantage of combination therapy and rec-
ommend a monotherapy explicitly for 
DMARD naïve patients. In DMARD in-
adequate responders, a clear recommen-
dation remains to be determined by rea-
son of missing evidence.
EULAR and German guidelines con-
form that adding glucocorticoids to 
DMARD monotherapy or combination 
therapy is beneficial for the patient. As 
evidence concerning doses and duration 
of glucocorticoid-bridging therapy is not 
available, both recommendations remain 
general and lack a more specific advice.
The EULAR recommendation 7 em-
phasizes the importance of prognostic fac-
tors for the further treatment decisions. A 
biological DMARD can be added to a syn-
thetic DMARD if poor prognostic factors 
Tab. 2 The 2010 EULAR recommendations for the management of rheumatoid arthritis with nonbiological and biological disease-modifying 
antirheumatic drugs [2]
Overarching principles
A Rheumatologists are the specialists who should primarily care for patients with RA
B Treatment of patients with RA should aim at the best care and must be based on a shared decision between the patient and the rheumatologist
C RA is expensive in regards to medical costs and productivity costs, both of which should be considered by the treating rheumatologist
15 recommendations for the management of RA
1 Treatment with synthetic DMARDs should be started as soon as the diagnosis of RA is made
2 Treatment should be aimed at reaching a target of remission or low disease activity as soon as possible in every patient; as long as the target has 
not been reached, treatment should be adjusted by frequent (every 1–3 months) and strict monitoring
3 MTX should be part of the first treatment strategy in patients with active RA
4 When MTX contraindications (or intolerance) are present, the following DMARDs should be considered as part of the (first) treatment strategy: 
 leflunomide, sulfasalazine, or injectable gold
5 In DMARD naïve patients, irrespective of the addition of GCs, synthetic DMARD monotherapy rather than combination therapy of synthetic 
DMARDs may be applied
6 GCs added at low to moderately high doses to synthetic DMARD monotherapy (or combinations of synthetic DMARDs) provide benefit as initial 
short-term treatment, but should be tapered as rapidly as clinically feasible
7 If the treatment target is not achieved with the first DMARD strategy, addition of a biological DMARD should be considered when poor prognostic 
factors are present; in the absence of poor prognostic factors, switching to another synthetic DMARD strategy should be considered
8 In patients responding insufficiently to MTX and/or other synthetic DMARDs with or without GCs, biological DMARDs should be started; current 
practice would be to start a TNF inhibitor (adalimumab, certolizumab, etanercept, golimumab, infliximab) which should be combined with MTX
9 Patients with RA for whom a first TNF inhibitor has failed should receive another TNF inhibitor, abatacept, rituximab, or tocilizumab
10 In cases of refractory severe RA or contraindications to biological agents or the previously mentioned synthetic DMARDs, the following synthetic 
DMARD might be also considered, as monotherapy or in combination with some of the above: azathioprine, cyclosporin A (or exceptionally, 
 cyclophosphamide)
11 Intensive medication strategies should be considered in every patient, although patients with poor prognostic factors have more to gain
12 If a patient is in persistent remission, after having tapered GCs, one can consider tapering biological DMARDs, especially if this treatment is 
 combined with a synthetic DMARD
13 In cases of sustained long-term remission, cautious titration of synthetic DMARD dose could be considered, as a shared decision between patient 
and doctor
14 DMARD naïve patients with poor prognostic markers might be considered for combination therapy of MTX plus a biological agent
15 When adjusting treatment, factors apart from disease activity, such as progression of structural damage, comorbidities and safety concerns should 
be taken into account
DMARD disease-modifying antirheumatic drug, GCs glucocorticoids, MTX methotrexate, RA rheumatoid arthritis, TNF tumor necrosis factor.
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are present in DMARD inadequate re-
sponders. Otherwise, a switch to anoth-
er synthetic DMARD strategy should be 
considered. At this point, the German 
guidelines strongly recommend a combi-
nation treatment of several DMARDs in 
DMARD inadequate responders but al-
so allow a biological DMARD as part of 
the combination therapy if poor prognos-
tic factors are present. The conclusion of 
both guidelines is similar, even if the order 
of the German statements accentuates the 
possibility to primarily utilize the full po-
tential of synthetic DMARD combination.
According to the available evidence 
and the approval as first biological agents, 
the initiation of a biological therapy was 
mainly equalized with the initiation of a 
TNF (tumor necrosis factor) inhibitor in 
EULAR recommendation 8. This priori-
ty status of TNF inhibitors has been with-
drawn in the German guidelines as the 
more recent biologic DMARDs abata-
cept and tocilizumab provided equiva-
lent evidence for their efficacy and safety 
and are also approved as first-line biolog-
ical agents. As indirect treatment compar-
ison show similar efficacy for all biolog-
ic agents except for anakinra, no specific 
agents are recommended at this point for 
preferable first line therapy.
The switch to a second biologic treat-
ment after an inadequate response to the 
first biological therapy remains identical 
in the EULAR and German guidelines – 
as second TNF inhibitor, abatacept, ritux-
imab or tocilizumab are possible agents 
without a specific ranking. However, full 
efficacy and safety data for a change to a 
defined second biologic agent following 
abatacept or tocilizumab are still lacking.
In the case of rheumatoid arthritis re-
fractory to several DMARDs and biolog-
ic agents, azathioprine, cyclosporin A and 
cyclophosphamide are specifically recom-
mended by EULAR due to existing evi-
dence on their efficacy, of course with re-
spect to their individual toxicity. However, 
German recommendation 10 has been re-
phrased to a more general statement in or-
der to also enable the application of other 
treatment options with the necessary re-
duction of evidence level to expert opin-
ion.
The final recommendations conform 
to the EULAR statements, even if recom-
mendations 12 and 13 are combined in the 
German guidelines – specific suggestions 
concerning the procedure in case of a sus-
tained remission are not provided due to 
the lack of evidence. Intensive treatment 
strategies and treatment adjustment con-
sidering structural progression, comor-
bidities and safety concerns are self-ev-
ident. EULAR recommendation 14 re-
fers to DMARD naïve patients again and 
creates the possibility to begin a biologic 
agent in combination with MTX as a first 
treatment strategy in individual patients 
with poor prognostic factors. By reason of 
order, this exceptional case was included 
and discussed in recommendation 3 of the 
German guidelines.
The aligned treatment algorithm sum-
marizes the recommendations and repre-
sents the current practice subjected to the 
different strategy steps in the course of the 
disease (. Fig. 1).
Taken together, the new 2012 Ger-
man recommendations provide an up-
date of the current evidence for the med-
ical treatment on rheumatoid arthritis on 
the basis of the 2010 EULAR recommen-
dations, providing an evidence-based re-
al-life set of recommendations for the use 
in the daily practice of every rheumatolo-
gist in (and outside) of Germany.
Abstract · Zusammenfassung
Z Rheumatol 2013 · 72:6–9  DOI 10.1007/s00393-012-1093-6
© The Author(s) 2012. This article is published with open access at link.springer.com
J. Wollenhaupt · K. Albrecht · K. Krüger · U. Müller-Ladner
The new 2012 German recommendations for treating rheumatoid 
arthritis. Differences compared to the European standpoint
Abstract
The German Society for Rheumatology re-
cently published guidelines for the sequen-
tial therapy of rheumatoid arthritis (RA). 
These recommendations were developed as 
a transition from the 2010 EULAR (EUropean 
League Against Rheumatism) recommenda-
tions to the national clinical practice and are 
based on an updated systematic literature re-
search and expert discussion. While most EU-
LAR recommendations have remained un-
changed, some were modified based on new 
evidence from randomized, controlled trials, 
current clinical practice, or national drug ap-
proval status. The guidelines also include a 
treatment algorithm for sequential therapy 
of RA with disease-modifying agents includ-
ing biologics.
Keywords
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Die neuen deutschen Empfehlungen zur Therapie der  
rheumatoiden Arthritis 2012. Unterschiede im Vergleich zu  
europäischen Standpunkten
Zusammenfassung
Die Deutsche Gesellschaft für Rheumatolo-
gie (DGRh) hat jüngst eine S1-Leitlinie zur se-
quenziellen medikamentösen Therapie der 
rheumatoiden Arthritis veröffentlicht. Die 
Empfehlungen beruhen auf einer Bewertung 
der EULAR (EUropean League Against Rheu-
matism) Recommendations vor dem Hinter-
grund der landesüblichen klinischen Prax-
is auf der Basis einer aktualisierten system-
atischen Literaturrecherche und eines Ex-
pertenurteils. Während sich viele EULAR-
Empfehlungen in der deutschen Version un-
verändert finden, ergaben sich für einige 
Änderungen auf der Grundlage neuer Evi-
denz aus randomisierten kontrollierten Stu-
dien, derzeitiger klinischer Praxis oder des 
nationalen Medikamentenzulassungssta-
tus. Konkretisiert werden die Empfehlungen 
durch einen überarbeiteten Therapiealgo-
rithmus mit Basistherapeutika einschließlich 
Biologika. Der vorliegende Kommentar soll 
– auch für englischsprachige Leser – die 
Gemeinsamkeiten und Unterschiede der 
deutschen Empfehlungen 2012 und der EU-
LAR Recommendations von 2010 erläutern.
Schlüsselwörter
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Fig. 1 8 Algorithm based on the German 2012 recommendations for the medical treatment of 
 rheumatoid arthritis. ABC abatacept, ADM adalimumab, CEZ certolizumab, ETC etanercept, GOM 
 golimumab, INX infliximab, RIX rituximab, TOZ tocilizumab, GC glucocorticoids, CiA ciclosporin A, HCQ 
hydroxychloroquine, LEF leflunomide, MTX methotrexate, SSZ sulfasalazine, TNF TNF inhibitors. *high 
disease activity, especially in combination with poor prognostic factors, **in case of MTX contraindica-
tion, ADM, CTZ, ETC are also approved in monotherapy, ***in case of MTX contraindication, TOZ is also  
approved in monotherapy and has demonstrated similar efficacy in monotherapy as well as in 
 combination with MTX
Ausschreibung  
Reisestipendium der DGORh
Die Deutsche Gesellschaft für Orthopä-
dische Rheumatologie (DGORh) schreibt 
auch 2013 ein Reisestipendium aus.
Das Stipendium ist mit 1.000 Euro dotiert.
Vorgesehen ist die Unterstützung einer 
internationalen Studienreise mit dem 
klinischen Schwerpunkt auf dem Gebiet 
der Orthopädischen Rheumatologie.
Voraussetzungen für eine Bewerbung: 
orthopädische AssistentInnen im fort-
geschrittenen Ausbildungsstadium oder 
FachärztInnen für Orthopädie/Unfallchirur-
gie mit Interesse an der „Orthopädischen 
Rheumatologie“.
Die Erfahrungen aus dieser Studienreise 
sollen publiziert und im Rahmen der Mit-
gliederversammlung der DGORh vorgetra-
gen werden.
In der Bewerbung soll das mit der Reise an-
gestrebte orthopädisch-rheumatologische 
Ziel erläutert werden.
Einsendeschluss für die Bewerbung ist der 
31.04.2013
Adressat: 
Prof. Dr. med. St. Rehart
Präsident der DGORh
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